IVERIC bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12, 2019
November 04 2019 - 4:05PM
Business Wire
- Company to Host a Zimura® R&D Symposium
for Investors on November 20, 2019 -
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will
report its third quarter 2019 financial and operating results on
Tuesday, November 12, 2019. Following the announcement, IVERIC
bio’s management team will host a live conference call and webcast
at 8:00 a.m. Eastern Time to discuss further details of the
clinical trial results previously announced by the Company for its
Zimura® (avacincaptad pegol) program in geographic atrophy (GA)
secondary to dry age-related macular degeneration (AMD), review the
Company’s financial results, and provide a general business
update.
To participate in this conference call, dial 888-208-1711 (USA)
or 323-994-2082 (International), passcode 5526863. A live,
listen-only audio webcast of the conference call can be accessed on
the Investors section of the IVERIC bio website at
www.ivericbio.com. A replay will be available approximately two
hours following the live call for two weeks. The replay number is
888-203-1112 (USA Toll Free), passcode 5526863.
Zimura R&D Symposium for Investors
The Company also announced that it will host a Zimura R&D
Symposium for Investors on Wednesday, November 20, 2019 from 8:00
a.m. to 10:00 a.m. Eastern Time in New York. The event will feature
a presentation of the previously announced clinical trial results
from the Company’s Zimura program on GA secondary to dry AMD and
will include discussions with retinal specialists and key opinion
leaders in dry AMD. On October 28, 2019, the Company announced that
Zimura met its pre-specified primary efficacy endpoint and reached
statistical significance in a Phase 2b randomized, controlled
clinical trial in GA secondary to dry AMD.
The event will be accessible via webcast on the IVERIC bio
website at www.ivericbio.com. For more information, please contact
Kathy Galante at kathy.galante@ivericbio.com or 212-845-8231.
About IVERIC bio
IVERIC bio is a biopharmaceutical company focused on the
discovery and development of novel treatment options for retinal
diseases with significant unmet medical needs. Vision is Our
Mission. For more information on the Company please visit
www.ivericbio.com.
Forward-looking Statements
Any statements in this press release about IVERIC bio’s future
expectations, plans and prospects constitute forward-looking
statements for purposes of the safe harbor provisions under the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors. Any
forward-looking statements represent IVERIC bio’s views only as of
the date of this press release. IVERIC bio anticipates that
subsequent events and developments will cause its views to change.
While IVERIC bio may elect to update these forward-looking
statements at some point in the future, IVERIC bio specifically
disclaims any obligation to do so.
ISEE-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191104005863/en/
Investors: IVERIC bio Kathy Galante, 212-845-8231 Vice
President, Investor Relations and Corporate Communications
kathy.galante@ivericbio.com or Media: SmithSolve Alex Van Rees,
973-442-1555 ext. 111 alex.vanrees@smithsolve.com
IVERIC bio (NASDAQ:ISEE)
Historical Stock Chart
From Mar 2024 to Apr 2024
IVERIC bio (NASDAQ:ISEE)
Historical Stock Chart
From Apr 2023 to Apr 2024